ライフサイエンスコーパス: mineralocorticoid receptor

1 s sensitive to antagonism of GPER but not of mineralocorticoid receptor.

2 roate antagonism versus agonism in the human mineralocorticoid receptor.

3 nt PHAI is characterized by mutations in the mineralocorticoid receptor.

4 ediated in part by aldosterone acting on the mineralocorticoid receptor.

5 progesterone-mediated activation of a mutant mineralocorticoid receptor.

6 icating that aldosterone was working via the mineralocorticoid receptor.

7 cocorticoid receptor, estrogen receptor, and mineralocorticoid receptor.

8 d is vital for dictating specificity for the mineralocorticoid receptor.

9 id receptor, they also bind and activate the mineralocorticoid receptor.

10 an be remedied by blocking activation of the mineralocorticoid receptor.

11 result of cortisol depletion of the cerebral mineralocorticoid receptors.

12 t cell line that stably expresses functional mineralocorticoid receptors.

13 owing aldosterone occupancy of cardiomyocyte mineralocorticoid receptors.

14 emide effect can be prevented by blockade of mineralocorticoid receptors.

15 binding to and activating glucocorticoid and mineralocorticoid receptors.

16 The glucocorticoid receptor and the mineralocorticoid receptor, 2 glucocorticoid-binding rec

17 Intercalated cell mineralocorticoid receptor ablation blunted, but did not

18 h circulating aldosterone, intercalated cell mineralocorticoid receptor ablation reduces chloride abs

19 d/or oxidative stress may also contribute to mineralocorticoid receptor activation in obesity.

20 However, obesity also causes mineralocorticoid receptor activation independent of ald

21 through transcriptional mechanisms involving mineralocorticoid receptor activation.

22 CC1 and outward K(+) channels, mediated by a mineralocorticoid receptor-ALD complex.

23 In addition to acting on mineralocorticoid receptors, aldosterone has been recent

24 Estrogen receptor alpha and mineralocorticoid receptor also contain functional NES,

25 um, whereas expression of mRNAs encoding the mineralocorticoid receptor and 11beta-HSD type 2 was hig

26 , tumor necrosis factor-alpha decreased both mineralocorticoid receptor and alpha1-adrenoceptor expre

27 harmacological studies and demonstrated both mineralocorticoid receptor and glucocorticoid receptor p

28 pendent nuclear translocation and binding of mineralocorticoid receptor and glucocorticoid receptor t

29 CC1 protein expression via the activation of mineralocorticoid receptors and post-transcriptional mod

30 These neurons express mineralocorticoid receptors and the enzyme 11-beta-hydro

31 es specific for the glucocorticoid receptor, mineralocorticoid receptor, and 11beta-HSD types 1 and 2

32 sues mRNAs encoding glucocorticoid receptor, mineralocorticoid receptor, and 11beta-HSD types 1 and 2

33 ding alterations in Na(+)/K(+)-ATPase, WNK1, mineralocorticoid receptor, and NEDD4L expression, as we

34 gen receptor alpha, glucocorticoid receptor, mineralocorticoid receptor, and progesterone receptor) a

35 addition of aldosterone, is mediated through mineralocorticoid receptors, and does not require de nov

36 treatment of patients with a combination of mineralocorticoid receptor antagonism (eplerenone) and a

37 mechanistic investigations have established mineralocorticoid receptor antagonism as the new treatme

38 Therefore, central mineralocorticoid receptor antagonism could increase com

39 ological changes do not readily reverse with mineralocorticoid receptor antagonism in adulthood.

40 le that, along with ACE-I and beta-blockers, mineralocorticoid receptor antagonism will become part o

41 In human pulmonary artery endothelial cells, mineralocorticoid receptor antagonism with spironolacton

42 Mineralocorticoid receptor antagonism, but not PAI-1 def

43 receptor antagonist pretreatment and not by mineralocorticoid receptor antagonism, suggesting a gluc

44 fine better the biologic mechanisms by which mineralocorticoid receptor antagonisms exert the observe

45 esting with evidence-based treatment using a mineralocorticoid receptor antagonist (MRA) and with lon

46 receptor-neprilysin inhibitor, and 50 mg of mineralocorticoid receptor antagonist (MRA) spironolacto

47 prilysin inhibitor (ARNI), beta-blocker, and mineralocorticoid receptor antagonist (MRA) were examine

48 'Apparent mineralocorticoid receptor antagonist (MRA)-resistant' h

49 nd renal function in patients treated with a mineralocorticoid receptor antagonist (MRA).

50 tics (yes/no), digitalis glycoside (yes/no), mineralocorticoid receptor antagonist (yes/no),and defib

51 Here we demonstrate that spironolactone, a mineralocorticoid receptor antagonist approved for clini

52 e intestinal peptide receptor 2, and a novel mineralocorticoid receptor antagonist are in phase II/II

53 angiotensin receptor-neprilysin inhibitor+BB+mineralocorticoid receptor antagonist combination therap

54 (-)-Finerenone is a nonsteroidal mineralocorticoid receptor antagonist currently in phase

55 iomethylspironolactone nor the more specific mineralocorticoid receptor antagonist eplerenone affecte

56 We evaluated the effect of the selective mineralocorticoid receptor antagonist eplerenone on rena

57 induced changes were blocked by applying the mineralocorticoid receptor antagonist eplerenone.

58 ed the effect of the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone on kidn

59 as foundational therapy, with addition of a mineralocorticoid receptor antagonist in patients with p

60 articipants, was prespecified as part of the Mineralocorticoid Receptor Antagonist in Type 2 Diabetes

61 lopment of CV injury were assessed using the mineralocorticoid receptor antagonist spironolactone (0,

62 The mineralocorticoid receptor antagonist spironolactone inh

63 We show here that the mineralocorticoid receptor antagonist spironolactone red

64 adding an angiotensin receptor blocker or a mineralocorticoid receptor antagonist to a regimen based

65 angiotensin receptor-neprilysin inhibitor+BB+mineralocorticoid receptor antagonist to implantable car

66 n angiotensin-converting enzyme inhibitor or mineralocorticoid receptor antagonist was associated wit

67 ceptor-neprilysin inhibitor + beta-blocker + mineralocorticoid receptor antagonist was used in 38%, 3

68 angiotensin-converting enzyme inhibitor or a mineralocorticoid receptor antagonist will decrease the

69 iotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist) and outcomes of p

70 ementing HK-fed Kcnmb1(-/-) with eplerenone (mineralocorticoid receptor antagonist) corrected the flu

71 In addition, 4671 (56%) were treated with a mineralocorticoid receptor antagonist, 2539 (30%) with d

72 Previous research suggests the mineralocorticoid receptor antagonist, eplerenone, is ef

73 ardiac defibrillator+ACE inhibitor or ARB+BB+mineralocorticoid receptor antagonist, implantable cardi

74 Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminur

75 iotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist, respectively.

76 These changes were prevented by the mineralocorticoid receptor antagonist, spironolactone.

77 We assessed the risk factors for mineralocorticoid receptor antagonist-related WRF and fo

78 l/L and when patients are not treated with a mineralocorticoid receptor antagonist.

79 ker, renin-angiotensin system inhibitor, and mineralocorticoid receptor antagonist; 40.3% versus 30.4

80 rein all patients with RH are treated with a mineralocorticoid-receptor antagonist without further te

81 ong-acting thiazide-like diuretic and an MR (mineralocorticoid receptor) antagonist, at maximal or ma

82 ngiotensin II receptor blockers (84.2%), and mineralocorticoid receptor antagonists (57.0%).

83 <95 mm Hg received significantly more often mineralocorticoid receptor antagonists (64.5% versus 43.

84 Mineralocorticoid receptor antagonists (MRA) improve out

85 Mineralocorticoid receptor antagonists (MRA) reduce morb

86 mproving quality of life followed by ARNi+BB+mineralocorticoid receptor antagonists (MRA)+SGLT2i (MD,

87 receptor blockers (ARB), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), and angiot

88 Consensus guidelines recommend the use of mineralocorticoid receptor antagonists (MRAs) for select

89 Mineralocorticoid receptor antagonists (MRAs) have becom

90 Mineralocorticoid receptor antagonists (MRAs) may attenu

91 The mineralocorticoid receptor antagonists (MRAs) spironolac

92 Three drug classes (mineralocorticoid receptor antagonists [MRAs], angiotens

93 Mineralocorticoid receptor antagonists administered at h

94 Mineralocorticoid receptor antagonists are a valuable ad

95 These findings suggest that the use of mineralocorticoid receptor antagonists coupled with GC t

96 beta-Blockers, calcium channel blockers, and mineralocorticoid receptor antagonists did not achieve s

97 Mineralocorticoid receptor antagonists improve outcomes

98 ace, but whether race influences efficacy of mineralocorticoid receptor antagonists in heart failure

99 19 trials of steroidal mineralocorticoid receptor antagonists including 4675 pa

100 in II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists increase ACE2 rec

101 findings suggest that safety and efficacy of mineralocorticoid receptor antagonists may differ by rac

102 The incidence of hyperkalemia caused by mineralocorticoid receptor antagonists may vary by race,

103 rimary objective was to assess the impact of mineralocorticoid receptor antagonists on cardiovascular

104 Mineralocorticoid receptor antagonists reduce morbidity

105 zed controlled trials in heart failure (HF), mineralocorticoid receptor antagonists reduced mortality

106 Mineralocorticoid receptor antagonists were independentl

107 Mineralocorticoid receptor antagonists were prescribed i

108 ism (e.g., thiazide-type diuretic agents and mineralocorticoid receptor antagonists) should be avoide

109 receptor blockers (ARBs), beta blockers, and mineralocorticoid receptor antagonists, and advanced dev

110 me inhibitors/angiotensin receptor blockers, mineralocorticoid receptor antagonists, and angiotensin

111 ors, Ang II type 1 receptor antagonists, and mineralocorticoid receptor antagonists, are a cornerston

112 , N-terminal pro-B-type natriuretic peptide, mineralocorticoid receptor antagonists, low voltage, ine

113 antagonist G-36, but was not affected by the mineralocorticoid receptor antagonists, spironolactone a

114 g body of evidence has suggested benefits of mineralocorticoid receptor antagonists, such as eplereno

115 Mineralocorticoid receptor antagonists, such as spironol

116 with heart failure and may be attenuated by mineralocorticoid receptor antagonists.

117 eta-blockers, and 32% (95% CI: 25%-39%) with mineralocorticoid receptor antagonists.

118 ocked by the GPER antagonist, but not by the mineralocorticoid receptor antagonists.

119 rolytes in patients with AF and HF receiving mineralocorticoid receptor antagonists.

120 s of beta-blocker, sacubitril/valsartan, and mineralocorticoid receptor antagonists.

121 on-like peptide 1 agonists, and nonsteroidal mineralocorticoid receptor antagonists.

122 edical therapies including beta-blockers and mineralocorticoid receptor antagonists.

123 Mineralocorticoid-receptor antagonists improve the progn

124 tensin-receptor blockers, beta-blockers, and mineralocorticoid-receptor antagonists.

125 do) promotes fibrosis in myocardium, and MR (mineralocorticoid receptor) antagonists (MRAs) improve c

126 nne muscular dystrophy mouse models and that mineralocorticoid receptors are present and functional i

127 Because cardiac mineralocorticoid receptors are protected from mineraloc

128 In contrast, an antagonist of the mineralocorticoid receptor as well as agonists of proges

129 tin, estrogen, androgen, glucocorticoid, and mineralocorticoid receptor, as well as sex hormone and c

130 confirmed the presence of glucocorticoid and mineralocorticoid receptors at these sites.

131 Although we have known that mineralocorticoid receptor blockade attenuates cardiovas

132 Mineralocorticoid receptor blockade before stress preven

133 Mineralocorticoid receptor blockade blunted leptin-induc

134 angiotensin-converting enzyme inhibition nor mineralocorticoid receptor blockade decreased the primar

135 l injury, only recently have we learned that mineralocorticoid receptor blockade improves pancreatic

136 T(1) receptor blockade using candesartan and mineralocorticoid receptor blockade using canrenoic acid

137 oxygen consumption, which was normalized by mineralocorticoid receptor blockade.

138 Mineralocorticoid receptor blockers have been shown to b

139 genetic causes of primary aldosteronism, and mineralocorticoid receptor blockers have now become an i

140 needs to be achieved in exploring the use of mineralocorticoid receptor blockers in less advanced sta

141 attributed to promiscuous activation of the mineralocorticoid receptor by cortisol, thereby promotin

142 2), allowing inappropriate activation of the mineralocorticoid receptor by endogenous glucocorticoid.

143 of inappropriate activation of cardiomyocyte mineralocorticoid receptors by aldosterone and reveal a

144 SD2 is inhibited and may allow access to the mineralocorticoid receptors by glucocorticoids.

145 Consistently, blockade of mineralocorticoid receptors by spironolactone treatment

146 Although aldosterone, acting via mineralocorticoid receptors, causes left ventricular (LV

147 excess, in which cortisol illicitly occupies mineralocorticoid receptors, causing hypertension and hy

148 (SAME), in which cortisol illicitly occupies mineralocorticoid receptors, causing sodium retention, h

149 id receptor did not, and studies with rat GR-mineralocorticoid receptor chimeras confirmed that the G

150 tructure and function, oxidative stress, and mineralocorticoid receptor-dependent gene transcription

151 d ejection fraction independently of classic mineralocorticoid receptor-dependent gene transcription.

152 across the groups but no evidence of classic mineralocorticoid receptor-dependent gene transcription.

153 uses cardiovascular and renal injury through mineralocorticoid receptor-dependent mechanisms.

154 ressure response to dietary sodium through a mineralocorticoid receptor-dependent pathway.

155 repressed TGF-beta transactivation, whereas mineralocorticoid receptor did not, and studies with rat

156 receptors (eg, atrasentan) and non-steroidal mineralocorticoid receptors (eg, finerenone).

157 ucocorticoid synthesis or glucocorticoid and mineralocorticoid receptors enabled the expression of em

158 roid hormone aldosterone and its partner the mineralocorticoid receptor-evolved by a stepwise Darwini

159 ium channel activity, despite principal cell mineralocorticoid receptor expression in the knockout mi

160 Furthermore, blunted vascular mineralocorticoid receptor expression might participate

161 Mineralocorticoid receptor expression was also blunted i

162 Both alpha1-adrenoceptor and mineralocorticoid receptor expressions studied in mouse

163 cause PHA1, underscore the important role of mineralocorticoid receptor function in regulation of sal

164 d by a persistent enhancement in hippocampal mineralocorticoid receptor function.

165 ralocorticoid receptor, we have screened the mineralocorticoid receptor gene (MLR) for variants and h

166 Mutations in the mineralocorticoid receptor gene (MR) cause adPHA1, but t

167 h circulating aldosterone, intercalated cell mineralocorticoid receptor gene ablation directly reduce

168 netic evidence is against involvement of the mineralocorticoid receptor gene, MLR, in PHA1.

169 , Na/H and anion exchangers, E-cadherin, and mineralocorticoid receptor genes as well as genes for th

170 The glucocorticoid and mineralocorticoid receptors (GR and MR) share considerab

171 -jun, which forms a nuclear complex with the mineralocorticoid receptor in a kidney fibroblast cell l

172 Ablation of the intercalated cell mineralocorticoid receptor in CCDs from aldosterone-trea

173 enetic study support a possible role for the mineralocorticoid receptor in the pathogenesis of cCSC.

174 le is known about the role of aldosterone or mineralocorticoid receptors in mediating adverse remodel

175 agonist eplerenone (EPL) to test the role of mineralocorticoid receptors in mediating the transition

176 locorticoids and the involvement of vascular mineralocorticoid receptors in murine endotoxic and huma

177 ss of aldosterone to otherwise non-selective mineralocorticoid receptors in the distal nephron.

178 Mineralocorticoid receptors in the inner medullary colle

179 glucocorticoids from otherwise nonselective mineralocorticoid receptors in the kidney.

180 D in the presence of NKCC1, K(+) channel and mineralocorticoid receptor inhibitors, revealed interact

181 e replacement suggests that occupancy of the mineralocorticoid receptor is responsible for the steroi

182 This study assessed whether the mineralocorticoid receptor iso/val polymorphism (rs5522)

183 in wild-type and intercalated cell-specific mineralocorticoid receptor knockout mice.

184 e recently discovered interaction of GC with mineralocorticoid receptors may counteract negative effe

185 one stimulates fibronectin synthesis through mineralocorticoid receptor (MCR) dependent activation of

186 rone (B), suggesting glucocorticoid (but not mineralocorticoid) receptor-mediated repression.

187 Vitamin D receptor, oestrogen receptor and mineralocorticoid receptor modulators regulate podocyte

188 e receptors-2 mGlu2, neuropeptide-Y NPY, and mineralocorticoid receptors MR).

189 Here we show that mineralocorticoid receptor (MR) activation by aldosteron

190 erations in glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) activation drive compuls

191 dent aldosteronism that results in excessive mineralocorticoid receptor (MR) activation.

192 g is the first step in hormone regulation of mineralocorticoid receptor (MR) activity.

193 with hormone replacement with the selective mineralocorticoid receptor (MR) agonist aldosterone, the

194 the steroid hormone aldosterone, which is a mineralocorticoid receptor (MR) agonist, is associated w

195 receptor protein expression as determined by mineralocorticoid receptor (MR) and glucocorticoid recep

196 mRNA; in hippocampal CA1, a reduction of the mineralocorticoid receptor (MR) and GR was observed.

197 Because adipocytes express mineralocorticoid receptor (MR) and MR blockade reduces

198 l function are thought to be mediated by the mineralocorticoid receptor (MR) and the glucocorticoid r

199 In rodents, mineralocorticoid receptor (MR) antagonism prevents AKI

200 ly, renin-angiotensin-aldosterone system and mineralocorticoid receptor (MR) antagonism reduces cardi

201 the administration of the novel nonsteroidal mineralocorticoid receptor (MR) antagonist BR-4628 can p

202 , was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro pote

203 n converting enzyme inhibitor lisinopril and mineralocorticoid receptor (MR) antagonist spironolacton

204 ion, or that were treated with the selective mineralocorticoid receptor (MR) antagonist spironolacton

205 rofibrotic effects, respectively, as did the mineralocorticoid receptor (MR) antagonist spironolacton

206 The mineralocorticoid receptor (MR) antagonist spironolacton

207 Administration of the mineralocorticoid receptor (MR) antagonist spironolacton

208 Here we report that treatment with the oral mineralocorticoid receptor (MR) antagonist spironolacton

209 mortality has led to increased interest in a mineralocorticoid receptor (MR) antagonist-based treatme

210 Mineralocorticoid receptor (MR) antagonists are effectiv

211 Mineralocorticoid receptor (MR) antagonists are the reco

212 Steroidal mineralocorticoid receptor (MR) antagonists are used for

213 FDA-approved mineralocorticoid receptor (MR) antagonists are used to

214 A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified a

215 cal and experimental studies have shown that mineralocorticoid receptor (MR) antagonists substantiall

216 ears as an alternative therapeutic option to mineralocorticoid receptor (MR) antagonists to reduce el

217 These effects were dependent on the mineralocorticoid receptor (MR) as they were abolished b

218 e aim of this study was to determine whether mineralocorticoid receptor (MR) blockade improves CFR in

219 as a deleterious hormone in the heart, with mineralocorticoid receptor (MR) blockade reducing mortal

220 TRPM7 current was inhibited by eplerenone, a mineralocorticoid receptor (MR) blocker, and GSK-650394,

221 Spironolactone, a nonselective mineralocorticoid receptor (MR) blocker, antagonizes ald

222 tective effects of Ly, a novel non-steroidal mineralocorticoid receptor (MR) blocker, through two exp

223 Mineralocorticoid receptor (MR) controls sodium homeosta

224 Mineralocorticoid receptor (MR) drugs have been used cli

225 ects on GR or TH expression in the VTA or on mineralocorticoid receptor (MR) expression in any of the

226 Mineralocorticoid receptor (MR) expression is increased

227 s shift may be mediated by activation of the mineralocorticoid receptor (MR) for cortisol.

228 s by protecting the inherently non-selective mineralocorticoid receptor (MR) from occupancy by endoge

229 ects of ANP and its second messenger cGMP on mineralocorticoid receptor (MR) function in rat colon su

230 1 mice also unexpectedly exhibited increased mineralocorticoid receptor (MR) gene expression.

231 sults on the subcellular localization of the mineralocorticoid receptor (MR) have been controversial.

232 After a survey of the entire brain for mineralocorticoid receptor (MR) immunoreactivity, we dis

233 and anxiety disorders, the role of the brain mineralocorticoid receptor (MR) in stress, depression, a

234 We studied the role of the mineralocorticoid receptor (MR) in the signaling that pr

235 Here, we targeted the role of the mineralocorticoid receptor (MR) in the stress-induced mo

236 esized that there is local expression of the mineralocorticoid receptor (MR) in the vasculature and t

237 The mineralocorticoid receptor (MR) is a hormone-dependent r

238 The mineralocorticoid receptor (MR) is a nuclear receptor an

239 The mineralocorticoid receptor (MR) is highly conserved acro

240 Activation of the mineralocorticoid receptor (MR) may promote dysfunctiona

241 The mineralocorticoid receptor (MR) mediates the Na(+)-retai

242 Relative to the low level of GR, mineralocorticoid receptor (MR) mRNA and protein express

243 Phosphorylation of human mineralocorticoid receptor (MR) on Ser-843, a residue pl

244 trogen receptor alpha (ERalpha), but not the mineralocorticoid receptor (MR) or ERbeta.

245 In contrast, aldosterone and the mineralocorticoid receptor (MR) primarily promote cardio

246 rials have emphasized the beneficial role of mineralocorticoid receptor (MR) signaling blockade in he

247 s thought to be caused by an exacerbation of mineralocorticoid receptor (MR) signaling, given that it

248 f nonsteroidal pyrazoline antagonists of the mineralocorticoid receptor (MR) that show excellent pote

249 Both stereoisomers bind to the mineralocorticoid receptor (MR) with a Ki value of appro

250 coid response [glucocorticoid receptor (GR), mineralocorticoid receptor (MR), 11beta-hydroxysteroid d

251 d hormone aldosterone acts by binding to the mineralocorticoid receptor (MR), a ligand activated tran

252 d hormone aldosterone acts by binding to the mineralocorticoid receptor (MR), a ligand-activated tran

253 gulates sodium homeostasis by activating the mineralocorticoid receptor (MR), a member of the nuclear

254 The mineralocorticoid receptor (MR), acting in the kidney, i

255 y cultures demonstrated specific GR, but not mineralocorticoid receptor (MR), activation and phosphor

256 receptor (ER), glucocorticoid receptor (GR), mineralocorticoid receptor (MR), and progesterone recept

257 r beta (Esr2), glucocorticoid receptor (Gr), mineralocorticoid receptor (Mr), and progesterone recept

258 eptors, the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR), both of which are prese

259 luding the glucocorticoid receptor (GR), the mineralocorticoid receptor (MR), corticotropin-releasing

260 aggravate CSCR and are known to bind to the mineralocorticoid receptor (MR), CSCR may be related to

261 We describe a mutation in the mineralocorticoid receptor (MR), S810L, that causes earl

262 affect the overall transcription of CRH, the mineralocorticoid receptor (MR), the serotonin transport

263 nsequence of mutations in genes encoding the mineralocorticoid receptor (MR), the three subunits of t

264 characterize the role of Rac1 GTPase for the mineralocorticoid receptor (MR)-mediated pro-fibrotic re

265 e corticosteroid hormone, aldosterone to its mineralocorticoid receptor (MR).

266 Although spironolactone can act at the mineralocorticoid receptor (MR; NR3C2), there is increas

267 xis occurs through a dual-receptor system of mineralocorticoid receptors (MR) and glucocorticoid rece

268 ression of glucocorticoid receptors (GR) and mineralocorticoid receptors (MR).

269 3C1 (glucocorticoid receptor; GR) and NR3C2 (mineralocorticoid receptor; MR) that encode for GRs and

270 Hippocampal mineralocorticoid receptor mRNA expression was increased

271 on of glucocorticoid hormones, which bind to mineralocorticoid receptors (MRs) and glucocorticoid rec

272 Mineralocorticoid receptors (MRs) in the brain play a ro

273 termine which brain receptors [high-affinity mineralocorticoid receptors (MRs) or low-affinity glucoc

274 Blocking brain mineralocorticoid receptors (MRs) reduces the high circu

275 Aldosterone activates mineralocorticoid receptors (MRs) to increase epithelial

276 a steroid hormone that signals through renal mineralocorticoid receptors (MRs) to regulate blood pres

277 chanism by which glucocorticoids, acting via mineralocorticoid receptors (MRs), decrease resilience t

278 and fluid homeostasis through binding to the mineralocorticoid receptors (MRs).

279 s in the glucocorticoid receptor (NR3C1) and mineralocorticoid receptor (NR3C2) genes with cCSC.

280 Predominant mineralocorticoid receptor occupation (ADC-LO group) res

281 ype b receptor, angiotensin type 1 receptor, mineralocorticoid receptor, or Nox isoforms 1 to 4.

282 its antitumor effects are independent of the mineralocorticoid receptor pathway.

283 Vascular mineralocorticoid receptors play a role in vascular tone

284 Mineralocorticoid receptors play an important role in me

285 ndent of blood pressure, but the role of the mineralocorticoid receptor remains unclear.

286 esource, the Androgen Receptor Resource, the Mineralocorticoid Receptor Resource, the Vitamin D Recep

287 We used the mineralocorticoid receptor-selective antagonist eplereno

288 sequences of aldosterone excess require full mineralocorticoid receptor signaling.

289 The effects of mineralocorticoid receptor stimulation are associated wi

290 ch is aldosterone, which selectively engages mineralocorticoid receptors to promote inflammation.

291 ENaC transcription independent of effects on mineralocorticoid receptor trans-activation.

292 uate aldosterone activation of cardiomyocyte mineralocorticoid receptors, transgenic mice overexpress

293 histochemical analysis of glucocorticoid and mineralocorticoid receptors using monoclonal antibodies

294 ng to Nguyen et al., local inhibition of the mineralocorticoid receptor via antagonists (spironolacto

295 eroid hormone aldosterone acting through the mineralocorticoid receptor, we have screened the mineral

296 ne is rapid, aldosterone binds to a specific mineralocorticoid receptor which then triggers gene acti

297 Aldosterone activates the intercalated cell mineralocorticoid receptor, which is enhanced with hypok

298 Finally, antagonism of the mineralocorticoid receptor will attenuate or abrogate ma

299 nfirmed by pharmacological inhibition of the mineralocorticoid receptor with spironolactone or eplere

300 on of glucocorticoid receptors with RU486 or mineralocorticoid receptors with spironolactone caused u